Ask AI

Highlights on Atopic Dermatitis

Share

Program Content

Activities

  • Atopic Dermatitis Highlights
    Research Highlights on Atopic Dermatitis: Practice-Changing Results from Recent Clinical Trials
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 21, 2020

  • New Data in AD
    My Take on the Most Clinically Relevant New Data in Atopic Dermatitis
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 10, 2020

    Expires: August 09, 2021

  • Selective JAK Inhibitors for AD
    Selective JAK Inhibitors for Atopic Dermatitis: Important Additions to the Treatment Toolbox
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 12, 2020

    Expires: August 11, 2021

  • Atopic Dermatitis Highlights
    Research Highlights on Atopic Dermatitis: Practice-Changing Results From Recent Clinical Trials
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 05, 2020

    Expires: November 04, 2021

Activities

BREEZE-AD1/2 Pooled Data Results
Pooled Data From BREEZE-AD1 and BREEZE-AD2 Examining the Efficacy and Safety of Baricitinib in Patients With Atopic Dermatitis and Atopic Comorbidities
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2020

JADE MONO-2 Results
JADE MONO-2 Study Results: Efficacy and Safety of Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 20, 2020

Upadacitinib Treatment Withdrawal and Retreatment
Efficacy and Safety of Treatment Withdrawal and Retreatment With Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2020

Dupilumab for Erythrodermic AD
Dupilumab for Erythrodermic AD: Results From a Pooled Subgroup Analysis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2020

BREEZE-AD5 Results
BREEZE-AD5 Study Results: Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: August 11, 2020

LIBERTY AD PEDS Results
LIBERTY AD PEDS Study Results: Efficacy and Safety of Dupilumab in Children Aged ≥ 6 to < 12 Yrs With Severe Atopic Dermatitis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 20, 2020

Provided by

ProCE Banner

Supporters

AbbVie Inc.

Pfizer, Inc.